Biotechnology

Internationally Acclaimed Forensic Scientist Dr. Henry C. Lee Dies, Leaving Remarkable Legacy

WEST HAVEN, Conn., March 28, 2026 /PRNewswire/ -- World-renowned forensic scientist Dr. Henry C. Lee passed away peacefully on Friday, March 27, at his home in Henderson, Nevada, displaying remarkable strength, grace and resilience during a brief illness. He was 87 years old. His passing was anno...

2026-03-28 06:24 5210

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights * KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-lin...

2026-03-26 13:13 7136

ScaleUp Bio Announces Fusionopolis Ventures Joining ADM as Shareholder

The partnership supports ScaleUp Bio's next phase of growth as a precision fermentation CDMO in Asia. SINGAPORE, March 26, 2026 /PRNewswire/ -- ScaleUp Bio Pte. Ltd. ("ScaleUp Bio ") today announced that Fusionopolis Ventures Pte. Ltd. ("FVPL"), a subsidiary of Economic Development Innovations Si...

2026-03-26 11:00 4564

XtalPi Holdings Announces Full Year 2025 Annual Results

HONG KONG, March 25, 2026 /PRNewswire/ -- Financial Highlights: * Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%. * Net profit for year 2025 reached reached RMB 134.6 million, while adjusted net profit amounted to RMB 258.2 million, making th...

2026-03-25 22:27 8402

Frost & Sullivan: Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition for Excellence in Platform-Driven Biological Innovation

The company is acknowledged for its scalable technology platform, application diversity, and customer-centered commercialization driving multi-industry adoption. SAN ANTONIO, March 25, 2026 /PRNewswire/ -- Frost & Sullivan

2026-03-25 21:00 2669

Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs

The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today * The Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal ...

2026-03-25 19:00 4286

Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials

New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challen...

2026-03-24 20:00 3455

Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study

Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today ann...

2026-03-24 20:00 2627

Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC

CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined T...

2026-03-24 17:24 4495

DualityBio (9606.HK) Announces 2025 Annual Results

HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing...

2026-03-24 15:55 4693

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study ev...

2026-03-24 11:32 4233

KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF

* Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase. * R&D Expenses was approximately RMB1319.68 million. * Loss for the period was RMB381.97 million, adjusted annual loss[1] was approxim...

2026-03-24 10:44 5100

Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phas...

2026-03-24 05:30 4070

Cambrex Advances US and European Expansions

EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles ...

2026-03-23 20:00 5075

Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies

MELBOURNE, Australia, March 23, 2026 /PRNewswire/ -- Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring ground...

2026-03-23 14:15 5612

Quality Protein No Longer a Luxury? Angel Yeast Shows How at FIC 2026

SHANGHAI, March 20, 2026 /PRNewswire/ -- Angel Yeast (SH600298) showcased its latest yeast protein R&D achievements and progress in global applications at FIC 2026 from March 17-19, 2026, reaffirming its commitment to making high-quality protein accessible to everyon...

2026-03-20 22:52 8068

Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations

SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase of 16.5%, and net profit of RMB 0.8270 billion....

2026-03-20 21:21 10934

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress. Dr. Jay Mei, Antengene's...

2026-03-20 17:14 8322

Tescan Opens New Demo Lab in Korea to Support Semiconductor Failure Analysis, Reliability, and Academic Research Across Asia-Pacific

Integrated demo lab and office site brings demonstrations, training, and workflow support closer to semiconductor and academic users across APAC. SEOUL, South Korea, March 20, 2026 /PRNewswire/ -- Tescan today announced the official opening of its upgraded Tescan Korea Demo Lab & Office in Seoul,...

2026-03-20 16:00 4609

Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs

SUZHOU, China and MÖLNDAL, Sweden, March 20, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleot...

2026-03-20 14:44 5609
1 ... 45678910 ... 185